The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Is Polypharmacy Associated with Frailty in Older People? Results From the ESTHER Cohort Study
Abstract
Objectives: To investigate the relationship between polypharmacy and frailty. Design: Longitudinal, observational cohort study. Setting: Saarland, Germany. Participants: 3,058 community‐dwelling adults aged between 57 and 84 years. Measurements: Frailty was assessed according to the frailty phenotype, described by Fried et al. Polypharmacy and hyperpolypharmacy were defined as the concomitant use of five or more and 10 or more drugs, respectively. We assessed associations between polypharmacy and prevalent and incident frailty within 3 years of follow‐up by logistic regression models controlled for multiple potential confounders including comorbidity. Additionally, cubic splines were used to assess dose–response associations. Results: Polypharmacy was reported in 39.1% (n = 1,194), and hyperpolypharmacy in 8.9% (n = 273) of participants. Prevalent frailty was present in 271 (8.9%) participants; 186 (9.3%) of 1,998 non‐frail participants with follow‐up data became frail within 3 years. After adjustment, polypharmacy and hyperpolypharmacy were associated with prevalent frailty with adjusted odds ratios (95% confidence interval) of 2.30 (1.60–3.31) and 4.97 (2.97–8.32), respectively. Polypharmacy (odds ratio ( OR ) 1.51 (1.05–2.16)) and hyperpolypharmacy ( OR 1.90 (1.10–3.28)) were also independent predictors of incident frailty. Furthermore, there was a moderate exposure–response relationship between the number of medicines and prevalent as well as incident frailty. Conclusion: Our study showed that polypharmacy is associated with frailty. Further research should address the potential benefit of reducing of inappropriate polypharmacy and better pharmacotherapeutic management for preventing medication‐associated frailty.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frailty in Older Adults: Evidence for a Phenotype
Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., Seeman, T., Tracy, R., Kop, W. J., Burke, G., et al. (2001) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/56.3.m146 · Cited by 24,907
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
Miller, M. D., Paradis, C. F., Houck, P. R., Mazumdar, S., Stack, J. A., Rifai, A. H., Mulsant, B., & Reynolds, C. F. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90005-n · Cited by 1,990
Jyrkkä, J., Enlund, H., Lavikainen, P., Sulkava, R., & Hartikainen, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2116 · Cited by 417
CPT: Pharmacometrics and Systems Pharmacology
van der Graaf, P. H. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.8 · Cited by 100
Cited by
Ofori-Asenso, R., Chin, K. L., Mazidi, M., Zomer, E., Ilomaki, J., Zullo, A. R., Gasevic, D., Ademi, Z., Korhonen, M. J., LoGiudice, D., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8398 · Cited by 618
The relationship between frailty and polypharmacy in older people: A systematic review
Gutiérrez‐Valencia, M., Izquierdo, M., Cesari, M., Casas‐Herrero, Á., Inzitari, M., & Martínez‐Velilla, N. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13590 · Cited by 480
An overview of prevalence, determinants and health outcomes of polypharmacy
Khezrian, M., McNeil, C. J., Murray, A. D., & Myint, P. K. (2020) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620933741 · Cited by 443
Kojima, G., Taniguchi, Y., Iliffe, S., Jivraj, S., & Walters, K. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.010 · Cited by 407
Metadata
- Authors
- Saum, K., Schöttker, B., Meid, A. D., Holleczek, B., Haefeli, W. E., Hauer, K., & Brenner, H.
- Venue
- Journal of the American Geriatrics Society
- Publisher
- Wiley
- Published
- 2016-12-26
- Volume
- 65
- Issue
- 2
- Pages
- e27-e32
- ISSN
- 0002-8614 (ISSN-L)
- 1532-5415
- OpenAlex
- W2563023099
- Cited by
- 203
- References
- 5
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.